InflaRx's Gohibic Gets Emergency Use Authorization from FDA for Covid-19 Hospitalized Patients
04 Abril 2023 - 2:42PM
Noticias Dow Jones
By Denny Jacob
InflaRx NV on Tuesday said Gohibic, a monoclonal anti-human
complement factor C5a antibody, was granted emergency use
authorization by the Food and Drug Administration.
The clinical-stage biopharmaceutical company said emergency use
authorization was for the treatment of Covid-19 in hospitalized
patients when initiated within 48 hours of receiving invasive
mechanical ventilation.
Shares surged 61% to $3.29 following the news.
InflaRx said its also completed meetings with teams of the
European Committee for Medicinal Products for Human Use regarding a
planned marketing authorization application with the European
Medicines Agency.
Chief Executive Niels Riedemann said that despite the
availability of vaccines and other Covid-19 treatments, many
patients still develop viral sepsis and progress to a critical
status, often requiring invasive mechanical ventilation.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 04, 2023 15:27 ET (19:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
InflaRx NV (NASDAQ:IFRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
InflaRx NV (NASDAQ:IFRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
